Key Drivers
- High gross/EBITDA
- Strong free cash
- Low asset turnover
AIAI Summary
ALC has shifted from deal-driven to a product‑led, organic recovery where near‑term valuation now hinges on successful Unity/AT‑IOL commercial execution and margin/FCF recovery rather than M&A upside; monitor Unity placements, AT‑IOL share gains, tariff trajectory, capex for rollouts, and quarterly margin improvement before increasing exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross/EBITDA
- •Strong free cash
- •Low asset turnover
ALC posts strong margins and free cash flow with solid liquidity and moderate leverage, but weak asset efficiency, large intangibles and rich multiples raise downside risk.
Price Behavior
Key Price Behavior Insights:
- •Clear downtrend
- •Deeply oversold
- •Elevated volatility
ALC has fallen roughly 10.9% over the last month into a clear short-term downtrend but is deeply oversold (RSI ~16), making a short-term bounce into the $81–$84 resistance likely unless price breaks below $73–$75 support.
Rapid ~10% drop over last month, raising short-term volatility risk
Sentiment & News
Key News Insights:
- •Product momentum
- •M&A setbacks
- •Buyback/expansion
ALC headlines show Alcon leaning on product-driven momentum despite missed estimates and aborted M&A, while AlgomaCentral pursues acquisitive growth and buybacks after strong results.
Mixed impact — Alcon's pipeline underpins medium-term upside but near-term sentiment is pressured by misses and deal failures, whereas Algoma's earnings and capital returns should support its share price
Similar Companies in Healthcare
Other companies in the same sector with AI ratings